Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: whenever (70), consistently (83), always (697)

Pembrolizumab_200mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (200mg) Regimen • Lymphoma – Pembrolizumab (200mg) Indication • Pem
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-200mg.pdf

Daratumumab

Description: Chemotherapy Protocol Myeloma Daratumumab Regimen • Myeloma – Daratumumab monotherapy Indication • Daratumumab monotherapy is rec
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab.pdf

DVd_Twice weekly_Daratumumab-Bortezomib-Dexamethasone_Cycles 1 to 8

Description: Chemotherapy Protocol Myeloma DVd (twice weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezo
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Twice-weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

DVd(Twice weekly)Daratumumab-Bortezomib-Dexamethasone Cycle 9 onwards

Description: Chemotherapy Protocol Myeloma Bortezomib (twice weekly) Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdTwice-weeklyDaratumumab-Bortezomib-Dexamethasone-Cycle-9-onwards.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone weekly Cycles 9 onwards

Description: Chemotherapy Protocol Myeloma DVd (weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 9 onwards) Regimen • Myeloma – Bortezomib
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-weekly-Cycles-9-onwards.pdf

Binimetinib-Encorafenib

Description: Chemotherapy Protocol SKIN CANCER Binimetinib-Encorafenib Regimen • Skin – Binimetinib-Encorafenib Indication •
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Binimetinib-Encorafenib.pdf

HSCTAlemtuzumabFludarabineMelphalan-Related_Methotrexate_GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-FLUDARABINE-MELPHALAN-METHOTREXATE (GvHD) RELATED DONOR CONDITIONING
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabFludarabineMelphalan-Related-Methotrexate-GvHD.pdf

GvHDProphylaxisMethotrexateTReplete

Description: Chemotherapy Protocol SUPPORT REGIMEN–GvHD PROPHYLAXIS METHOREXATE – T Replete Allograft Graft versus Host Disease (GvHD) Prophylaxis T
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/GvHDProphylaxisMethotrexateTReplete.pdf

Pentostatin

Description: Chemotherapy Protocol HAIRY CELL LEUKEMIA PENTOSTATIN Regimen • HCL – Pentostatin Indication • Hairy cell leukaemia Toxicity Drug
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/HCL/Pentostatin.pdf

Von Hippel-Lindau disease (VHL) - patient information

Description: Information about von Hippel-Lindau (VHL) disease.
Url: /Media/UHS-website-2019/Patientinformation/Genetics/Von-Hippel-Lindau-disease-VHL-1438-PIL.pdf

621 to 630 of 768

Previous … 61 62 63 64 65 … Next